{"id":20616,"date":"2023-11-02T08:10:58","date_gmt":"2023-11-02T08:10:58","guid":{"rendered":"https:\/\/clinlabint.com\/?p=20616"},"modified":"2023-11-02T08:10:58","modified_gmt":"2023-11-02T08:10:58","slug":"diasys-lpa-21-fs","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/diasys-lpa-21-fs\/","title":{"rendered":"DiaSys Lp(a) 21 FS"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

DiaSys Lp(a) 21 FS<\/h1>\/ in Product News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n
\"\"<\/div><\/div><\/div>
\n

– Excellent accurate measurement in molarity of Lp(a) ( nmol\/L )
\n– Alternative measurement in mass ( mg\/ dL )
\n– Isoform-insensitive test with harmonized reagent and calibrators
\n– Liquid-stable and ready-to-use system reagent
\n– Standardized to international WHO-IFCC reference material SRM2B
\n– DiaSys Lp(a) 21 FS applicable on any clinical chemistry analyzer<\/h3>\n

\u00a0<\/strong><\/h3>\n

<\/p>\n

Lp(a) stands out as one of the last challenges in lipid management, and this recognition is well-founded. Elevated blood Lp(a) levels are primarily due to genetic variations in the Lp(a) gene that encodes for apo(a) and cannot be lowered after age 2 by diet, exercise or current lipid-lowering therapies. It is an independent risk factor and should be measured once in all subjects at intermediate or high risk for cardiovascular disease ( CVD ) or coronary heart disease ( CHD ).<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n
\n